Duale BRD4 und PLK1 Inhibitoren im Rhabdomyosarkom

to related objects

Alternative title: Dual BRD4 and PLK1 Inhibitors in rhabdmyosarcoma

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Deutsch

Notes: Berlin, Medizinische Fakultät Charité - Universitätsmedizin Berlin, Dissertation, 2025

Keyword: Enzyminhibitor
Inhibitor
Zelllinie
Rhabdomyosarkom

Event: Veröffentlichung

(where): Berlin

(who): Medizinische Fakultät Charité - Universitätsmedizin Berlin

(when): 2025

Creator: Timme, Natalie

DOI: 10.17169/refubium-45713

URN: urn:nbn:de:kobv:188-refubium-46003-6

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Timme, Natalie
Medizinische Fakultät Charité - Universitätsmedizin Berlin

Time of origin

2025

Other Objects (12)

Synergistische Wirkung des BRD4-Inhibitors MK-8628 und PLK1-Inhibitors Volasertib in vorklinischen Modellen des Medulloblastoms

Dual HDAC–BRD4 inhibitors endowed with antitumor and antihyperalgesic activity

Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer

Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

Identification of Plk1 type II inhibitors by structure-based virtual screening

Preparation data of the bromodomains BRD3(1), BRD3(2), BRD4(1), and BRPF1B and crystallization of BRD4(1)-inhibitor complexes

BRD4 inhibitor JQ1 inhibits and reverses mechanical injury-induced corneal scarring

Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer

Non‐canonical cM et regulation by vimentin mediates Plk1 inhibitor–induced apoptosis

Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion

BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma

Synergistische Wirkung des BRD4-Inhibitors MK-8628 und PLK1-Inhibitors Volasertib in vorklinischen Modellen des Medulloblastoms

Dual HDAC–BRD4 inhibitors endowed with antitumor and antihyperalgesic activity

Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer

Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

Identification of Plk1 type II inhibitors by structure-based virtual screening

Preparation data of the bromodomains BRD3(1), BRD3(2), BRD4(1), and BRPF1B and crystallization of BRD4(1)-inhibitor complexes

BRD4 inhibitor JQ1 inhibits and reverses mechanical injury-induced corneal scarring

Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer

Non‐canonical cM et regulation by vimentin mediates Plk1 inhibitor–induced apoptosis

Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion

BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma

Synergistische Wirkung des BRD4-Inhibitors MK-8628 und PLK1-Inhibitors Volasertib in vorklinischen Modellen des Medulloblastoms

Dual HDAC–BRD4 inhibitors endowed with antitumor and antihyperalgesic activity

Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer

Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

Identification of Plk1 type II inhibitors by structure-based virtual screening

Preparation data of the bromodomains BRD3(1), BRD3(2), BRD4(1), and BRPF1B and crystallization of BRD4(1)-inhibitor complexes

BRD4 inhibitor JQ1 inhibits and reverses mechanical injury-induced corneal scarring

Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer

Non‐canonical cM et regulation by vimentin mediates Plk1 inhibitor–induced apoptosis

Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion

BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Duale BRD4 und PLK1 Inhibitoren im Rhabdomyosarkom

Object Details

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Time of origin

Other Objects (12)

Synergistische Wirkung des BRD4-Inhibitors MK-8628 und PLK1-Inhibitors Volasertib in vorklinischen Modellen des Medulloblastoms

Dual HDAC–BRD4 inhibitors endowed with antitumor and antihyperalgesic activity

Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer

Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

Identification of Plk1 type II inhibitors by structure-based virtual screening

Preparation data of the bromodomains BRD3(1), BRD3(2), BRD4(1), and BRPF1B and crystallization of BRD4(1)-inhibitor complexes

BRD4 inhibitor JQ1 inhibits and reverses mechanical injury-induced corneal scarring

Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer

Non‐canonical cM et regulation by vimentin mediates Plk1 inhibitor–induced apoptosis

Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion

BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma

Synergistische Wirkung des BRD4-Inhibitors MK-8628 und PLK1-Inhibitors Volasertib in vorklinischen Modellen des Medulloblastoms

Dual HDAC–BRD4 inhibitors endowed with antitumor and antihyperalgesic activity

Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer

Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

Identification of Plk1 type II inhibitors by structure-based virtual screening

Preparation data of the bromodomains BRD3(1), BRD3(2), BRD4(1), and BRPF1B and crystallization of BRD4(1)-inhibitor complexes

BRD4 inhibitor JQ1 inhibits and reverses mechanical injury-induced corneal scarring

Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer

Non‐canonical cM et regulation by vimentin mediates Plk1 inhibitor–induced apoptosis

Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion

BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma

Synergistische Wirkung des BRD4-Inhibitors MK-8628 und PLK1-Inhibitors Volasertib in vorklinischen Modellen des Medulloblastoms

Dual HDAC–BRD4 inhibitors endowed with antitumor and antihyperalgesic activity

Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer

Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

Identification of Plk1 type II inhibitors by structure-based virtual screening

Preparation data of the bromodomains BRD3(1), BRD3(2), BRD4(1), and BRPF1B and crystallization of BRD4(1)-inhibitor complexes

BRD4 inhibitor JQ1 inhibits and reverses mechanical injury-induced corneal scarring

Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer

Non‐canonical cM et regulation by vimentin mediates Plk1 inhibitor–induced apoptosis

Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion

BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma

Related objects

Reset password